1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,022 | 0,024 | 21.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.08. | Baidu Wenku Wangpan's GenFlow Announces Chinese Name 'Kuku AI' | 25 | AASTOCKS | ||
| 03.08. | Genflow Biosciences PLC Announces Patent Update | 206 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 03.08. | Genflow Biosciences - Patent Update | 1 | RNS | ||
| 13.07. | Genflow meldet positive Studiendaten bei Hunden und sichert sich LNP-Partnerschaft | 1 | Investing.com Deutsch | ||
| 13.07. | Genflow reports positive dog trial data, secures LNP partnership | 1 | Investing.com | ||
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 13.07. | Genflow Biosciences PLC Announces Mid-Year Operational and Corporate Summary | 359 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / July 13, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), an emerging leader in the field of longevity research, provides a mid-year... ► Artikel lesen | |
| 13.07. | Genflow Biosciences - Mid-Year Operational and Corporate Summary | - | RNS | ||
| 29.06. | Genflow Biosciences PLC Announces Result of AGM | 282 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / June 29, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, is pleased to announce... ► Artikel lesen | |
| 29.06. | Genflow Biosciences - Result of AGM | 1 | RNS | ||
| 22.06. | Genflow Biosciences PLC Announces Participation at BIO International Convention 2026 | 267 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / June 22, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, today announces Gad... ► Artikel lesen | |
| 22.06. | Genflow Biosciences - Participation at BIO International Convention 2026 | - | RNS | ||
| 17.06. | Genflow präsentiert im Oktober Daten zur Gentherapie bei alternden Hunden | 2 | Investing.com Deutsch | ||
| 17.06. | Genflow to present aged dog gene therapy data in October | 4 | Investing.com | ||
| 17.06. | Genflow Biosciences PLC - Company to present at Animal Longevity Summit 2026 | 249 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 17.06. | Genflow Biosciences - Company to present at Animal Longevity Summit 2026 | 2 | RNS | ||
| 04.06. | Genflow Biosciences PLC Announces Notice of AGM | 482 | ACCESS Newswire | Notice of Annual General Meeting and Board Changes LONDON, UK / ACCESS Newswire / June 4, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the... ► Artikel lesen | |
| 04.06. | Genflow Biosciences - Notice of AGM | 1 | RNS | ||
| 08.05. | Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity | 408 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| 08.05. | Genflow Biosciences - Exercise of Warrants and Issue of Equity | 2 | RNS | ||
| 30.04. | Genflow Biosciences PLC Announces Final Results | 235 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 51,16 | +0,45 % | CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money? | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,110 | -5,09 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| DENALI THERAPEUTICS | 21,270 | -0,28 % | DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock? | ||
| VOYAGER THERAPEUTICS | 2,864 | -0,90 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| BIOAGE LABS | 8,520 | +4,86 % | BioAge Labs, Inc.: BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates | First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of... ► Artikel lesen | |
| LINEAGE CELL THERAPEUTICS | 0,943 | +1,51 % | Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call | ||
| BIOPHYTIS | 0,100 | 0,00 % | XFRA 6XB3: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOPHYTIS NAM. EO... ► Artikel lesen | |
| SERINA THERAPEUTICS | 2,240 | -8,20 % | Serina Therapeutics, Inc.: Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates | Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252 -Top-line data from the single-ascending-dose arm targeted for the first half of 2027 - Appointment of Farrell... ► Artikel lesen | |
| LONGEVERON | 0,840 | -0,57 % | Longeveron Appoints Nirav Jhaveri as Chief Financial Officer | Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 38,660 | 0,00 % | Kaum zu fassen: Die unglaubliche Biotech-Story von Amylyx Pharmaceuticals | Der Biotech-Sektor ist immer wieder für faustdicke Überraschungen gut - sowohl negativ als auch positiv. Bei Amylyx Pharmaceuticals gibt es am Dienstag keine zwei Meinungen: Die Aktie des Biotech-Unternehmens... ► Artikel lesen | |
| MODERNA | 123,92 | -0,26 % | BREAKING: AKTIONÄR-Depotwert Moderna explodiert! | Ein Durchbruch der mRNA-Technologie im Bereich der Onkologie: Moderna und der Entwicklungspartner Merck & Co haben die lang ersehnten ersten Ergebnisse der Phase-3-Studie INTerpath-001 mit Intismeran... ► Artikel lesen | |
| BIONTECH | 99,80 | -0,05 % | Schlafender Biotech-Riese vor der nächsten Wachstumsphase? BioNTech, Emyria und die neue Macht der Datenplattformen | ||
| QIAGEN | 37,565 | -3,02 % | DAX Gewinner am Mittwoch: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| BEAM THERAPEUTICS | 29,760 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 375,86 | 0,00 % | Raymond James raises Praxis Precision Medicines price target on pipeline outlook |
Das Unternehmen GENFLOW BIOSCIENCES PLC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,001 (+2,38 %) liegt der Kurs bei 0,022 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.